Citius Oncology Inc (NASDAQ:CTOR) does about 128.15K shares in volume on a normal day but saw 69901635 shares change hands in the recent trading day. The company now has a market cap of 66.54M USD. Its current market price is $0.93, marking an increase of 39.85% compared to the previous close of $0.67. The 52 week high reached by this stock is $49.00 whilst the lowest price level in 52 weeks is $0.55.
Citius Oncology Inc (CTOR) has a 20-day trading average at $0.7695 and the current price is -98.10% off the 52-week high compared with 68.91% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.0386 and its 200-day simple moving average is $3.7749. If we look at the stock’s price movements over the week, volatility stands at 33.93%, which decreases to 18.86% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 54.94 to suggest the stock is neutral.
The consensus objective for the share price is $3.00, suggesting that the stock has a potential upside of 69.0% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on November 27, 2024 when Maxim Group initiated the stock to “Buy” and issued a price target of $3.
The current price level is 20.87%, -10.45%, and -75.36% away from its SMA20, SMA50, and SMA200 respectively, with the CTOR price moving above the 50-day SMA on current market day. Citius Oncology Inc (CTOR) stock is up 30.99% over the week and -21.85% over the past month. Its price is -19.13% year-to-date and -91.51% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at 0 and 0 for whole year. Expected sales for next quarter are $8.6M, which analysts say will come at $28.68M for the current fiscal year and next year at $72.88M. In addition, estimates put the company’s current quarterly revenue at an average of $5.74M.
To reach the target analysts have set, the stock logically needs to grow 69.0 percent from here.
Outstanding shares total 71.55M with insiders holding 95.07% of the shares and institutional holders owning 0.89% of the company’s common stock. The company has a return on investment of -46.26%. The beta has a value of 0.30. Price to book ratio is 1.61.
